This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Best Practice Update on <em>Clostridium difficile</em> Infection: Focus on Prevention, Treatment and Recurrence

Best Practice Update on Clostridium difficile Infection: Focus on Prevention, Treatment and Recurrence


Slide Lecture Series

Time to Complete

1 hour


January 4, 2019


March 1, 2020
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Pharmacy Credits

Pharmacists may earn 1.00 CPE Credit (0.10 CEU) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website, and free registration on the ASHP website is required). Your certificate will save on and will not be included in your myCME CME History.

Accredited Provider

This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).

Commercial Supporter

Supported by an educational grant from Merck.

Program Description

Clostridium difficile infection (CDI) is the most common healthcare associated infection the United States and the most common cause of mortality in patients with gastroenteritis. Treatment of CDI is evolving with a greater emphasis on prevention of recurrence also known as sustained clinical response. These changes will require education to clinicians on these major changes. This session will provide a state-of-the art update on best practice treatment of CDI with a focus on guideline updates, antibiotic stewardship strategies, and sustained clinical response.

Intended Audience

This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of patients with Clostridium difficile infection (CDI).

Educational Objectives

At the conclusion of this knowledge-based educational activity, participants should be able to:

  • Review updates of Clostridium difficile infection (CDI) guideline recommendations
  • Apply antibiotic stewardship strategies for the primary prevention of CDI
  • Discuss treatment of CDI with a focus on sustained clinical response

Conflict Of Interest Disclosure Policy

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.


Kevin W. Garey, PharmD, MS, FASHP, Activity Chair
Professor and Chair
Department of Clinical Sciences and Administration
University of Houston College of Pharmacy
Houston, Texas

Dr. Garey discloses the following:
Research Support: Merck, Inc., Summit Therapeutics, and Tetraphase

A. Krishna Rao, MD, MS
Assistant Professor of Internal Medicine
University of Michigan
Ann Arbor, Michigan

Dr. Rao discloses the following:
Research support (Co-investigator): Merck, Inc.

Accredited Provider Disclosure

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Society of Health-System Pharmacists designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


In order to receive credit, participants must view the activity and complete the post-test and program evaluation. Participants must score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue